MedPath

Radioprotective effect of melatonin in patient with rectal cancer

Phase 2
Conditions
Condition 1: rectal cancer. Condition 2: radiation injury.
Benign neoplasm: Rectum
Exposure to ionizing radiation
Registration Number
IRCT2016021626586N1
Lead Sponsor
Babol University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

60 patients with rectal cancer; aged 40 to 60 years with radiotherapy and chemotherapy same regime that still have not done surgery Exclusion criteria: patients with autoimmune diseases (purpura); von Willebrand's disease; patients that of aspirin drugs; sulfadiazine; daunorubicin use; individuals who previously had chemotherapy or radiotherapy; people who have a history of depression or suicidal feeling

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Thrombocytopenia. Timepoint: before beginning treatment and at the end of treatment. Method of measurement: CBC.
Secondary Outcome Measures
NameTimeMethod
Thrombocytopenia. Timepoint: before beginning treatment and at the end of treatment. Method of measurement: CBC.
© Copyright 2025. All Rights Reserved by MedPath